FIELD: medicine.
SUBSTANCE: invention relates to method for reducing of LDL-cholesterol and/or triglyceride level increased due to therapy by HIV protease inhibitors in HIV-infected subjects. According to invention Atazanavir is administered in combination with other HIV protease inhibitor, metabolized cytochrom P450 monooxygenase in therapeutically effective amounts.
EFFECT: effective treatment due to Atazanavir ability to cytochrom P450 monooxygenase inhibition; increased concentration of HIV protease inhibitors without preparation dose.
3 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION | 2005 |
|
RU2367439C2 |
| COMBINATION OF ANTI-HIV INHIBITORS OF REVERSE TRANSCRIPTASE AND PROTEASE | 2005 |
|
RU2368380C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL DRUG AND PHARMACOKINETICS IMPROVER | 2017 |
|
RU2745204C2 |
| METHOD AND COMPOSITION FOR PREVENTING HIV INFECTION, PREVENTING AND TREATING HIV-CAUSED OR HIV-ASSOCIATED DISEASES, INCLUDING AIDS | 2010 |
|
RU2516931C2 |
| NEW ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2508105C2 |
| QUINOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING VIRAL INFECTION | 2016 |
|
RU2723016C2 |
| AZAPEPTIDE DERIVATIVES | 2008 |
|
RU2448958C2 |
| 1,2,5-OXADIAZOLE DERIVATIVES, HAVING ANTI-HIV ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITING HIV-1 INTEGRASE | 2012 |
|
RU2515413C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING HIV-INFECTION, METHOD FOR PREPARING AND METHOD OF USING | 2013 |
|
RU2543322C1 |
| COMPOSITION FOR REDUCTION OF CERAMIDE CONTENT | 1996 |
|
RU2203047C2 |
